Maze Therapeutics (MAZE) Gains Momentum, Is It Still 49% Below Fair Value?

Maze Therapeutics (MAZE) has drawn attention after recent trading left the stock at $31.69 as of 25 October 2026. Investors are weighing that price against mixed return figures across different time frames.

Recent trading tells a mixed story for Maze Therapeutics. The 30-day share price return of 18.03% and 90-day gain of 14.69% point to building short term momentum, while the year-to-date share price decline of 20.32% and modest 1-year total shareholder return of 1.38% suggest a longer term reset in expectations.

Compare Maze Therapeutics' recent swing with a curated set of similar biotech stories by scanning 21 high quality undiscovered gems that are still flying under most investors' radar.

Maze Therapeutics now carries the profile of an early-stage biotech with ambitious kidney and metabolic programs, yet a share price that has run hard in the last month. Is that business story fairly reflected in today's tag?

Most Popular Narrative: 49% Undervalued

Maze Therapeutics is framed as materially cheaper than a widely followed fair value of $62.55, given the last close at $31.69. That gap is pinned on how the pipeline could reshape the business over the next few years.

Progression of MZE829 from Phase II HORIZON data that showed a mean 36% uACR reduction in APOL1 mediated kidney disease and higher uACR reductions in the FSGS subgroup could support eventual label defining studies that expand Maze Therapeutics’ addressable patient pool and potential future revenue base.

Find out how 1 investors see Maze Therapeutics as 49% undervalued.

Result: Fair Value of $62.55 (UNDERVALUED)

Still, the narrative around Maze Therapeutics can crack if profit margins do not shift meaningfully from the current US$133.6 million loss, or if ongoing equity raises keep diluting shareholders.

Find out about the key risks to this Maze Therapeutics narrative.

Next Steps

Mixed signals like these deserve your own final call, so move fast, review the full picture, and weigh the 1 key reward and 4 important warning signs.

Looking for more Maze Therapeutics style ideas?

If Maze Therapeutics has you thinking harder about risk, reward, and timing, do not stop with one ticker. Broader context can sharpen every decision.

• Target higher income potential by reviewing steady payers through the 5 dividend fortresses, so you are not relying on one stock for yield.
• Hunt for quality at a fair tag using the 29 high quality undervalued stocks, which highlights companies combining strong fundamentals with prices that lag their underlying metrics.
• Protect your downside by scanning the 30 resilient stocks with low risk scores, then compare those resilient profiles against what you see in Maze Therapeutics.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com